Maxim Group set a $12.00 target price on Cytosorbents Corporation (NASDAQ:CTSO) in a research note published on Thursday morning. The brokerage currently has a buy rating on the medical research company’s stock.

Several other research firms have also recently commented on CTSO. ValuEngine upgraded Cytosorbents Corporation from a sell rating to a hold rating in a research note on Wednesday, September 6th. B. Riley restated a buy rating and issued a $11.25 target price on shares of Cytosorbents Corporation in a research note on Wednesday, August 2nd. HC Wainwright set a $13.00 target price on Cytosorbents Corporation and gave the company a buy rating in a research note on Tuesday, August 8th. Finally, Aegis restated a buy rating and issued a $9.00 target price on shares of Cytosorbents Corporation in a research note on Tuesday, July 25th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The company has an average rating of Buy and an average target price of $10.45.

Shares of Cytosorbents Corporation (NASDAQ:CTSO) traded up 0.83% during trading on Thursday, reaching $6.05. 67,797 shares of the company traded hands. Cytosorbents Corporation has a 12 month low of $3.30 and a 12 month high of $6.70. The stock’s 50 day moving average price is $5.86 and its 200-day moving average price is $4.89. The stock’s market cap is $170.20 million.

Cytosorbents Corporation (NASDAQ:CTSO) last released its earnings results on Monday, August 7th. The medical research company reported ($0.04) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.02. The firm had revenue of $3.57 million for the quarter, compared to analysts’ expectations of $3.29 million. Cytosorbents Corporation had a negative return on equity of 529.95% and a negative net margin of 80.56%. On average, equities research analysts expect that Cytosorbents Corporation will post ($0.27) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at

A hedge fund recently raised its stake in Cytosorbents Corporation stock. PNC Financial Services Group Inc. lifted its stake in shares of Cytosorbents Corporation (NASDAQ:CTSO) by 145.2% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 38,000 shares of the medical research company’s stock after purchasing an additional 22,500 shares during the period. PNC Financial Services Group Inc. owned 0.14% of Cytosorbents Corporation worth $163,000 at the end of the most recent quarter. 6.89% of the stock is owned by institutional investors.

About Cytosorbents Corporation

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.

Analyst Recommendations for Cytosorbents Corporation (NASDAQ:CTSO)

Receive News & Stock Ratings for Cytosorbents Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corporation and related stocks with our FREE daily email newsletter.